Lithium Therapy in Bipolar Disorder and Neurodegenerative Disease
This community investigates the clinical use of lithium salts, primarily for managing bipolar disorder, and explores its potential role in treating or preventing neurodegenerative conditions such as Alzheimer’s disease.
The research focuses heavily on long-term lithium therapy, monitoring serum levels, and managing side effects like nephrogenic diabetes insipidus and toxicity. Recurring themes include the comparison of lithium with other mood stabilizers like sodium valproate, and the investigation of lithium’s molecular mechanisms, particularly its inhibition of glycogen synthase kinase-3 (GSK-3). While the core is clinical psychiatry, a significant strand of work examines lithium’s impact on cognitive decline, mild cognitive impairment, and Alzheimer’s disease, often through the lens of repurposing the drug for neuroprotective effects.
The largest share of the community's output is found in lithium research, accounting for 3.1% of all lithium research and comprising 7,005 papers within this group.
This community includes 9,668 papers, with the American Journal of Psychiatry, The Lancet, and the British Journal of Psychiatry being the most frequent publication venues.
Recent work continues to examine the long-term renal effects of lithium use, including declines in glomerular filtration rate, and investigates emerging interactions between lithium and newer therapies such as GLP-1 agonists in bipolar disorder patients.